Investigational drug · Phase 2
KCBT-1083
Also called: BEBT-109
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "KCBT-1083"
First trial start
2022
Apr 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KCBT-1083", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- EGFR Exon 20 Insertion Mutation
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "KCBT-1083" as an intervention, largest first.
- Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung CancerRecruiting
BeBetter Med IncIndustry
NCT06706713 · 200 participants (planned) · Start Apr 15, 2022 · Primary completion Dec 31, 2025
Drug: BEBT-109 Capsule · For: Non-Small Cell Lung Cancer; EGFR Exon 20 Insertion Mutation
Sites: Guangzhou, China; Changsha, China
BeBetter Med IncIndustry
NCT06514027 · 30 participants (planned) · Start Aug 28, 2024 · Primary completion Jun 2027
Drug: BEBT-109 Capsules; Pemetrexed Disodium for Injection and 2 more · For: Non Small Cell Lung Cancer
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety outcomes of emerging EGFRߛTKIs for patients with nonߛsmall cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and metaߛanalysis.
Xie K, Wang J, Jiang J, et al. · Oncol Lett 2025
- First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.
Zeng L, Song L, Liu L, et al. · Med 2024
- BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer.
Fan F, Zhou M, Ye X, et al. · Transl Oncol 2021
Also in development for Non Small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.